Oligomer-Cannabinoid Conjugates for Peripheral Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid drugs for pain management, obesity, and inflammation face limitations due to significant side effects and the inability to selectively target peripheral receptors without crossing the blood-brain barrier, leading to central nervous system side effects.
Innovation Solution
Development of chemically modified cannabinoids with a cannabinoid residue covalently attached via stable or degradable linkages to water-soluble, non-peptidic oligomers, such as poly(alkylene oxide), to reduce blood-brain barrier penetration while maintaining bioactivity and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabinoids are administered for pain management, obesity, and inflammation, then therapeutic efficacy is improved, but significant side effects occur due to crossing the blood-brain barrier
Solution Approach 1:
The cannabinoid molecule is segmented into two parts: the active cannabinoid residue and a water-soluble oligomer component. This segmentation allows the oligomer to act as a delivery vehicle that prevents blood-brain barrier crossing while the cannabinoid residue maintains its therapeutic activity at peripheral receptors
Solution Approach 2:
The water-soluble oligomer serves as an intermediary component that mediates between the lipophilic cannabinoid residue and the aqueous biological environment. This intermediary prevents the cannabinoid from crossing the blood-brain barrier while maintaining its ability to interact with peripheral CB2 receptors
2Ease of operation
If cannabinoids cross the blood-brain barrier to reach peripheral receptors, then peripheral receptor targeting is achieved, but central nervous system side effects occur
Solution Approach 1:
The conjugate structure creates local quality differences: the oligomer portion provides water solubility and prevents blood-brain barrier penetration, while the cannabinoid residue portion maintains affinity for peripheral CB2 receptors. This localized functional differentiation achieves peripheral selectivity without CNS exposure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified cannabinoids effectively reduce side effects by minimizing blood-brain barrier crossing, enhancing selective peripheral receptor targeting, and maintaining therapeutic efficacy, thus improving the desirability of cannabinoid-based therapies.
Implementation Method 1
a water-soluble, non-peptidic oligomer... to reduce blood-brain barrier penetration
Data Source
AI summary
The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.